Dear editor, Philadelphia negative myeloproliferative neoplasm primarily includes Polycythemia Vera, Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) [1] . Majority of the ET and PMF patients have mutations in JAK2 (JAK2 V617F) or CALR genes. Mutations mapping to the juxtamembrane region of the thrombopoietin receptor MPL (exon 10) have been described in 5-10% of PMF patients and 1% of ET patients, who were negative for JAK2 and CALR mutations [2] . These MPL mutations are gain of function mutations leading to receptor activation in the absence of thrombopoietin binding with constitutive activation of the JAK-STAT signaling. Spontaneous activation of this receptor leads to uncontrolled overactivity resulting in myeloproliferative neoplasms [3] .
The MPL gene located on chromosome 1p34 has 12 exons coding for the thrombopoietin receptor. [2, 4] . While Sanger sequencing (MPL exon 10) has the advantage of screening all these six mutations, it is limited by its analytical sensitivity. Mutations occurring at allelic levels below 15% may not be detected by routine Sanger sequencing [5] .
We screened a total of 80 DNA samples from patients diagnosed with ET or PMF, based on peripheral blood and bone marrow findings, in the Department of Haematology, Christian Medical College, Vellore between Jan 2010 and July 2017. All these samples were negative for JAK2 V617F and CALR mutations. DNA extraction from peripheral blood leukocytes was done using a commercial kit (Gentra Puregene Blood kit, Qiagen, Hilden, Germany) according to the manufacturer's instructions. Screening for MPL mutations was done by both bidirectional Sanger sequencing and Allele specific PCR.
As c.1544G [ T, c.1543_1544TG [ AA, c.1543_1544TG [ GC and c.1514G [ A mutations account for 98% of MPL mutations, we aimed to design an assay capable of detecting each of these mutations with high sensitivity and specificity [5] . We devised an Allele specific oligonucleotide PCR (ASO-PCR) based approach, using previously published protocols with specific modifications, for screening the four common MPL mutations [5] . While Furtado et al. performed gene scan analysis with capillary electrophoresis using labeled primers, we used an ASO-PCR based approach which is a cost effective alternative to gene scan analysis without compromising the sensitivity. Primers targeting the wild type and mutant sequences were used in this assay and the specificity of the primers was based on a 3 0 mismatch in the primer sequence [5] . The PCR reaction was carried out in two tubes simultaneously for each sample. which were characterized by sequencing. The PCR amplicons are electrophoresed in an agarose gel along with a 100 base pair ladder and the interpretation of the results was based on the difference in product size. MPL mutation was identified in 12 out of 80 patients (15%) using either of the two methods. Sanger sequencing and allele specific PCR identified the mutations in 10 and 12 patients respectively. We did not identify c.1514G
Although direct sequencing has an advantage of screening all possible mutations in exon 10 of MPL it is limited by its low sensitivity which is a major concern while dealing with somatic mutations. We performed serial dilution assay to establish the Limit of Detection (LOD) of ASO-PCR and its superiority to Sanger sequencing in terms of assay sensitivity. ASO-PCR showed a clear positivity for MPL mutation when the mutant allelic burden was as low as 1.56% (Fig. 2) . On the other hand Sanger sequencing produced false negative results when the allelic burden falls below 10%. Although mutant allele concentrations below 1.5% can be picked up by a repeat PCR with an increased number of amplification cycles in the ASO-PCR program (supplement table 1), the clinical significance of such low level mutant allele burden is questionable at screening level. The specificity of the assay was also validated by using 40 known control samples [including healthy controls, known CML patients with BCR-ABL1 translocation, diagnosed MPN patients with other MPN related (JAK2/CALR) mutations and MPN patients with MPL mutations other than the one targeted by the specific ASO primer pair]. Other methods such as real time quantitative PCR, high-resolution melting and pyrosequencing have been described in the literature for the detection of MPL mutations [6, 7] . Although they have a similar or even better sensitivity (ranging from 0.1 to 3%) to ASO-PCR, they are limited by various factors like availability and cost issues.
ASO-PCR is a cost effective and sensitive screening platform for MPL mutations that can be used by most laboratories. PCR Mastermix (12.5 ll 9 2 per sample), primers (1.5 ll each 9 2 per sample) and an electrophoresis setup are sufficient to perform the assay while sequencing demands all the above along with sequencing and clean up procedure reagents and a capillary electrophoresis unit which is not available in most of the labs in our country. In our experience we find the cost of sequencing to be approximately twice as high as ASO-PCR for MPL mutations. Further, the turnaround time for the assay is also less (4 h from PCR reaction setup till interpretation of the result) when compared to Sanger sequencing, which is generally a two day procedure in our lab. However ASO-PCR has its own limitations as well. ASO-PCR cannot be used to quantitate mutant allele burdens and presence of mutations other than the four mutations cannot be ruled out. This can be possibly overcome by using a third optional tube with primers specific to the two rare mutations [c.1544G [ C (W515S) and c.1543T [ A or c.1543T [ C (W515R)]. Laboratories can also use a combined approach where the ASO-PCR negative patients are screened subsequently by Sanger sequencing for the rare MPL exon 10 mutations. In our study, sequencing did not yield any additional mutation other than the four common mutations tested by allele specific PCR while the high sensitivity of allele specific PCR over Sanger sequencing enabled us to pick up two additional positive cases.
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